FLUXTRIN OTC


Gastro-resistant tablets 14
scheduling status
S2
registration number
47/11.4.3/0318
What FLUXTRIN OTC is and what it is used for
Short-term treatment of reflux symptoms such as heartburn and regurgitation in adults.
dosage
The recommended dose is 20 mg esomeprazole (one tablet) per day. It might be necessary to take the tablet for 2 – 3 consecutive days to achieve improvement of symptoms. The duration of treatment is up to 2 weeks. Once complete relief of symptoms has occurred, treatment should be discontinued. If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should consult a doctor. Special populations Impaired renal function: Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution. Impaired hepatic function: Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum daily dose of 20 mg FLUXTRIN OTC should be used. Elderly: Dose adjustment is not required in the elderly. Paediatric population: There is no relevant use of FLUXTRIN OTC in the paediatric population below 18 years of age for the indication of short-term treatment of reflux symptoms (e.g., heartburn and acid regurgitation).
how to take
The tablets should be swallowed whole with liquid. The tablets should not be chewed or crushed.
What FLUXTRIN OTC contains
Each gastro-resistant tablet contains esomeprazole magnesium equivalent to 20 mg esomeprazole. Contain sugar: sucrose 14,6 mg and lactose monohydrate 31,88 mg.
other ingredients
Sugar spheres (sucrose and maize starch), ethylcellulose, magnesium stearate, povidone (K-90), light magnesium oxide, sodium lauryl sulfate, polysorbate 80, methacrylic acid – ethyl acrylate copolymer, diethyl phthalate, talc (purified), cellulose microcrystalline, silica colloidal anhydrous, lactose monohydrate, maize starch, copovidone (K-28), macrogol 8000, crospovidone (type A), silica colloidal anhydrous, hypromellose, titanium dioxide (E171), ferric oxide red (E172), opacode S-1-17823 black ink (contains shellac glaze, isopropyl alcohol, iron oxide black, n-butyl alcohol, propylene glycol and ammonium hydroxide).
Therapeutic classification
Drugs for acid-related disorders, proton pump inhibitors.
© 2026 SAHPRA. ALL RIGHTS RESERVED